Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation (OTCQB: BRCNF; TSX: BU) regularly issues news updates that focus on its progress in plant-based protein innovation and commercialization. As a company that describes itself as a global technology leader in high-performance plant-based proteins for the food and beverage industry, its announcements often highlight developments in product performance, customer adoption, and financing activities.
News items from Burcon frequently cover milestones in commercial production and sales of its branded ingredients, such as Puratein® C canola protein, FavaPro™ fava protein, Peazazz® C pea protein, and Solatein™ sunflower protein. The company reports on first commercial production runs, initial commercial sales, and commercial sales orders for its next generation proteins, as well as the progression of customers from evaluation to purchase orders across its pea, canola, and fava platforms.
Burcon’s releases also include updates on scientific and technical validation of its ingredients. For example, the company has reported on a University of Guelph study in which its pea and sunflower proteins were found to outperform a competitor’s pea protein in a plant-based cheese application, with commentary on melt, stretch, and sensory attributes.
In addition, the company’s news flow features financial and corporate developments, including fiscal results, revenue trends from protein sales and contract manufacturing services, non-brokered private placements of convertible debentures, short-term loan agreements, and insider participation in financings. Governance-related announcements, such as board appointments and shareholder meeting results, are also part of its disclosures.
Investors and industry observers who follow Burcon’s news can track how the company describes its commercialization progress, customer pipeline, manufacturing partnerships, and capital structure as it advances its plant-based protein business.
Burcon (OTCQB: BRCNF) appointed Chris Bunio to its board effective April 29, 2026, and announced departures of directors Jeanne McCaherty and Richard Nazur Jr..
Bunio brings nearly 30 years in technology, founded and operationalized TheoryMesh in 2021, and previously spent 18 years at Microsoft in global senior roles. McCaherty joined Burcon in July 2021; Nazur joined in September 2025.
Burcon (OTCQB: BRCNF) closed the final tranche of a non‑brokered private placement of convertible debentures for an aggregate principal amount of $6.9 million on April 27, 2026. The final tranche raised $2.9 million, with insiders subscribing about $4.4 million in aggregate.
The Company received approximately $2.35 million cash from the final tranche after offsetting $546,678 payable to an entity related to an insider. Proceeds will fund inventory, labor, production capability, infrastructure planning, loan repayments and general corporate purposes.
Burcon (OTCQB: BRCNF) reported operational and commercial progress on April 20, 2026. The company achieved record production, raising average daily output by approximately 40% versus the calendar Q1 average, and expanded to more than 20 buying customers across multiple food and beverage categories. Burcon and manufacturing partner RE ProMan are evaluating additional capacity expansion to meet rising demand across products such as Peazzaz, FavaPro and Puratein.
Management said the milestones support scaling toward 2026 goals while focusing on efficient growth and customer onboarding.
Burcon (OTCQB:BRCNF) closed the second tranche of a non-brokered private placement of convertible debentures for $2.75 million on February 27, 2026, bringing cash raised to $4.0 million to date.
The Private Placement totals up to $6.9 million and the Company expects to close a final tranche (a $2.90 million non-cash loan conversion) prior to April 24, 2026. Insiders have subscribed for $2.7 million in principal so far and the Company will rely on MI 61-101 exemptions for related-party participation.
Burcon (OTCQB: BRCNF) announced that all matters at its 2026 special meeting of shareholders held February 20, 2026 were duly approved. Shareholders approved the Convertible Debenture Financing and an amendment to the expiry date of insider-held warrants.
Disinterested shareholder approval was obtained where required. The company filed detailed voting results on SEDAR+ and expects to close the Convertible Debenture Financing on or about February 24, 2026, according to the company.
Burcon (OTCQB: BRCNF, TSX: BU) reported fiscal Q3 results for the period ended December 31, 2025, with revenue of $739,000 (up ~1100% year-over-year) and nine-month revenue of $1.439 million (up ~325% YoY). Burcon closed a $1.25 million tranche of a $6.9 million private placement and drew a related-party $480,000 loan to bridge funding while scaling production at Galesburg.
Net loss for nine months was $10.7 million and cash was $1.3 million at quarter end; the company expects the final private placement tranche to close on or about February 24, 2026.
Burcon (OTCQB: BRCNF) will hold a special shareholders meeting on February 20, 2026 (virtual) to seek disinterested shareholder approval to amend certain insider warrants. The company is extending the expiry of outstanding warrants totaling 1,544,249 common shares to June 30, 2027.
The Board has already amended Non-insider Warrants (effective February 19, 2026). Amendments for insider-held warrants are subject to disinterested shareholder approval at the Meeting. Management says exercising warrants could provide cash to accelerate capacity expansion.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, February 11, 2026 at 5:00 p.m. ET to discuss fiscal 2026 third quarter results for the period ended December 31, 2025.
A press release with the Company's financial results will be issued prior to the call; a webcast link and archived replay will be available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF, TSX: BU) said it increased its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million on January 9, 2026, citing strong investor demand. Insiders and manufacturing partner owners have committed a minimum of $5.0 million. The TSX granted conditional approval pending compliance, including receipt of disinterested shareholder approval. Management reaffirmed a revenue target of more than $10 million for calendar 2026.
Burcon (OTCQB: BRCNF) closed the first tranche of a non‑brokered private placement of convertible debentures for $1.25 million, part of an aggregate financing of up to $6.3 million. Insiders and manufacturing partner owners committed at least $5.0 million in principal. The financing is conditionally approved by the TSX and the final tranche requires disinterested shareholder approval expected after a special meeting on February 20, 2026. Each debenture carries 15% interest, 48‑month maturity, and is convertible at $1.60 per share (with pre‑funded warrant option). Proceeds will fund production scale‑up, infrastructure planning, general corporate purposes and repay a short‑term loan.